CliffBio
small molecule

PIQRAY

ALPELISIB

Loss of exclusivityApril 2033latest FDA-listed patent expiry
CompanyNovartis →View the full company profile on CliffBio

Drug detail

Brand namePIQRAY
Active ingredientALPELISIB
Strength200MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2019
Marketing statusRX

Listed patents

PatentExpiresType
8227462April 2033substance, product
8476268September 2029substance, product

Regulatory exclusivity

CodeExpires
I-937January 2027

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

PIQRAY patent cliff — loss of exclusivity April 2033 | CliffBio